Feds Might Regulate CBD as a Food Ingredient

Home | Canna Law Blog | Feds Might Regulate CBD as a Food Ingredient The CBD Product Safety and Standardization Act (the Act) indicates that the Feds might regulate CBD as a food ingredient, and that it may lead to regulation of other cannabinoids. If the Feds regulate CBD as a food ingredient, it could seriously change the game (in a good way) for hemp CBD companies. On December 2, Congress introduced the Act, which is a bipartisan bill that would establish federal standards for food and beverage products containing hemp-derived cannabidiol (CBD). If enacted, the Act would: Require the Food and Drug Administration (FDA) to regulate CBD similarly to any other food ingredient; Allow the FDA to regulate CBD as a food additive; Subject these products to enforceable safeguards to ensure safety and accountability; and Task the FDA with establishing CBD content limits, packaging and labeling requirements, and determining in which categories of food CBD is appropriate for use. In a press release, U.S. Representative Kathleen Rice (NY-04), one of the sponsors of the Act, commented that: "CBD products are exploding in popularity, but the lack of federal regulation surrounding them has put consumers at risk and left businesses looking for clarity. The bipartisan CBD Product Safety and Standardization Act will establish the clear regulatory framework needed to provide stability for business and ensure unsafe products stay off the shelves.” In other words, the goal of this new legislation is to protect consumers, provide CBD companies with much needed regulatory clarity, eliminate bad actors and dangerous CBD products in the market, and provide stability for farmers, manufacturers, distributors and retailers. If you follow this blog, you know we share Rep. Rice’s opinion on the need for CBD regulation. Indeed, the FDA’s failure to act has resulted in the emergence of a vast, unregulated market in which the safety of many CBD products is questionable. Most states have developed their own sets of rules and regulations for the manufacture, sale, and marketing of CBD products. This, in turn, has resulted in a patchwork of requirements that have made it incredibly difficult – if not impossible – for industry actors to ensure compliance. So in that sense, the Act is great news – in fact, it is supported by some major industry leaders, including Consumer Brands Association and U.S. Hemp Roundtable. But what is worth noting here is the narrow scope of this legislation. Unlike other federal legislations that have been introduced these past few years, including the Hemp Access and Consumer Safety Act (S. 1698) -- which proposes to legalize the use of hemp-derived cannabinoids, including CBD, in foods and dietary supplements -- the Act only addresses the regulation of CBD, which is one of many hemp-derived cannabinoids sold on the market. It will be interesting to see how these federal bills progress through Congress (if at all) and whether federal lawmakers ultimately legalize the use of all hemp-derived cannabinoids or only a few in finished products intended for human consumption. We'll continue to monitor these issues and will report on future developments. Check Out Our Cannabis Law Services Share Twitter Facebook LinkedIn E-mail Comment Fred Rocafort Fred leads Harris Sliwoski’s intellectual property practice and is the coordinator of the firm’s international team. Much of Fred’s practice consists of helping cannabis businesses protect their brands. He also works with entrepreneurs and companies entering the Web3 space, a new frontier for IP law. Prior to joining Harris Sliwoski, Fred worked overseas for more than a decade, in both government and private sector roles. Fred is a regular contributor to the award-winning China Law Blog and Canna Law Blog. Fred began his career overseas as a U.S. consular officer in Guangzhou, China, where he advocated for fairer treatment of American companies and citizens in China and for stronger intellectual property rights enforcement. After entering the private sector, Fred worked at a Shanghai law firm as a foreign legal advisor and later joined one of the oldest American law firms in China, helping foreign companies navigate the Chinese legal environment. He also led the legal team at a Hong Kong-based brand protection consultancy, spending most of his time out in the field, protecting clients against counterfeiters and fraudsters in Greater China, Southeast Asia and Latin America. In addition to his IP work, as a native Spanish speaker, Fred works closely with different Harris Sliwoski teams on Latin America and Spain matters. Fred also provides advice to cannabis industry participants and other businesses on import and export transactions. Fred is an ardent supporter of FC Barcelona—and would be even in the absence of Catalan forebears who immigrated to Puerto Rico in the mid-1800s. Harris Sliwoski Attorney Read more posts [email protected] Read More FDA, Federal law and policy, Hemp/CBD Related Posts September 25, 2026 DEA Enforcement in a Changing Cannabis Landscape: Rescheduling, Hemp, and What Comes Next September 17, 2026 The Supreme Court May Decide if Cannabis-Related Residency Requirements are Unconstitutional September 16, 2026 A $31.8 Million Cannabis-Related Verdict That a Federal Court Wouldn’t Enforce September 15, 2026 Jason Adelstone Moderates Federal Cannabis Policy Discussion at IgniteIt Denver September 11, 2026 Medical Marijuana in Schedule III Survives Its First Major Challenge September 10, 2026 How to Acquire a Colorado Cannabis License September 4, 2026 The Intoxicating Hemp Products Ban Was Delayed a Month. Now What? August 31, 2026 Is the Global Shift to the Right Threatening International Cannabis Reforms? August 28, 2026 Oregon Cannabis Roundup: Fall 2026 August 26, 2026 Five Bills Every California Cannabis Operator Needs to Track in 2026 August 14, 2026 California Cannabis Contracts After Rescheduling: Why Your Contracts Need a Second Look August 4, 2026 DCC License Conversions After Rescheduling: How and When to Split A/M Licenses in California August 3, 2026 The Contradictions of Cannabis Law: From the United States to International Treaties July 28, 2026 What California Operators Must Do After Rescheduling: DEA Registration, License Restructuring, and 280E July 24, 2026 Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test Leave a comment Cancel reply